文献速递眼底病与葡萄膜炎

保加利亚、德国和美国晚期年龄相关性黄斑变性的经济负担

Economic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

本研究采用患病率法疾病成本经济模型,估算保加利亚、德国和美国晚期年龄相关性黄斑变性(AMD)的社会经济负担。

要点

  • 直接医疗成本仅占总成本10%至13%,非医疗成本占主导。
  • 德国和保加利亚最大贡献为幸福感损失(67%和76%),美国为生产力损失(42%)。

核心结论

  • 晚期AMD对美国、德国和保加利亚患者及照护者造成沉重负担。
  • 三国中幸福感损失和生产力损失对总经济负担贡献较大。
  • 作者认为实施降低AMD发病率、延缓疾病进展和减轻人文负担的措施可能有助于降低晚期AMD的经济负担。

研究设计与样本

  • 采用患病率法疾病成本经济模型估算晚期AMD归因成本。
  • 通过主要数据收集获取卫生资源利用、幸福感和生产力数据,模型所需其他数据来自已发表文献。
  • 数据收集时间为2021年1月至2022年3月,分析时间为2022年4月至7月。
  • 研究对象为保加利亚、德国和美国50岁以上、一眼或双眼诊断为晚期AMD(nAMD或任何形式GA)的患者及照护者,通过保加利亚和德国眼科诊所及美国在线通讯和社交媒体招募。
  • 共纳入128例晚期AMD患者(80例女性,占62%;120例60岁及以上,占94%)和61名照护者(43名女性,占70%;55名45岁及以上,占91%)。

主要发现

  • 所有国家中,直接医疗成本占总成本10%至13%。
  • 德国和保加利亚总经济负担最大贡献为幸福感降低(分别为67%和76%),美国为生产力损失(42%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Age-related macular degeneration (AMD) is a highly prevalent and debilitating retinal condition that affects more than 200 million people globally, with the severe late-stage forms-neovascular AMD (nAMD) and geographic atrophy (GA)-affecting more than 11 million people globally. However, much is unknown about the economic burden of the disease. OBJECTIVE: To estimate the economic burden associated with late-stage AMD in Bulgaria, Germany, and the US at the societal level. DESIGN, SETTING, AND PARTICIPANTS: This study used the prevalence approach cost-of-illness economic modeling to estimate costs attributable to late-stage AMD. Data on health care resource utilization, well-being, and productivity were obtained via primary data collection. Additional data required for the model were sourced from available published literature. Data were collected from January 2021 to March 2022, and analyzed from April to July 2022. Participants older than 50 years residing in Bulgaria, Germany, and the US who were diagnosed with late-stage AMD (nAMD or any form of GA) in 1 or both eyes and caregivers who care for people diagnosed with late-stage AMD were recruited through ophthalmological clinics in Bulgaria and Germany and via online newsletters and social media in the US. MAIN OUTCOMES AND MEASURES: The main outcomes were direct medical costs (disease-related health care expenditures), indirect medical costs (care support and assistive technology), well-being cost (loss of well-being), and productivity cost (loss in productivity due to the diseases for both patient and caregivers). RESULTS: Of the 128 individuals with late-stage AMD in this study, 80 (62%) were female, and 120 (94%) were aged 60 years or older. Of the 61 caregivers, 43 (70%) were female and 55 (91%) were aged 45 years or older. Estimated per-annum total costs attributable to late-stage AMD were €449.5 million ($512.5 million) in Bulgaria, €7.6 billion ($8.6 billion) in Germany, and €43.2 billion ($49.4 billion) in the US. Across all countries, 10% to 13% of the total cost incurred was attributed to direct medical costs. In Germany and Bulgaria, the biggest contributor to the total economic burden was reduced well-being (67% and 76%, respectively), whereas in the US, loss of productivity (42%) was the biggest contributor. CONCLUSIONS AND RELEVANCE: The findings of this study indicate a substantial burden of late-stage AMD on patients and caregivers in the US, Germany, and Bulgaria. Across the 3 countries, reduced well-being and loss of productivity were relatively large contributors to the total economic burden. Implementing measures to reduce AMD incidence, delay disease progression, and alleviate humanistic burden may help reduce the economic burden of late-stage AMD.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Paudel N, Brady L, Stratieva P, et al. Economic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US. JAMA Ophthalmol. 2024. PMID: 39480444. doi:10.1001/jamaophthalmol.2024.4401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。